The information on the Joint HTA assessment of ZYNTEGLO has been updated - see the news on the Beneluxa website: beneluxa.org/news1

Beneluxa - Ministers of Health acknowledge the importance of a HTA on Covid Therapeutics: see beneluxa.org/news3

Which new pharmaceuticals will enter the market to treat Alzheimer’s Disease between 2022 and 2027? See a new report of the DTF Horizon Scanning of the Beneluxa Initiative - beneluxa.org/Alzheimer

A new publication of the Domain Taskforce Horizon Scanning of the Beneluxa Initiative describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments: see beneluxa.org/Haemophilia

Beneluxa is reaching out to other collaborations: international experience sharing on negotiations of new pharmaceuticals - see the news on our website: beneluxa.org/news2

The Beneluxa initiative identified four impactful medicines suitable for a joint evaluation- read more: beneluxa.org/candidates_for…

Belgium, Ireland and the Netherlands jointly agreed to end the negotiation discussions on reimbursement with the manufacturer of Libmeldy, a gene therapy for the treatment of metachromatic leukodystrophy (MLD). More info: beneluxa.org/Libmeldy

The Beneluxa Initiative welcomes the strengthening of the FINOSE collaboration - congratulations to Denmark and the FINOSE group! Read more: beneluxa.org/news2

Beneluxa statement at EPSCO Council in June 2023: Applying a needs-driven approach to pharmaceutical innovation For more details: beneluxa.org/EPSCO_Council_…

At the end of June 2023, the Beneluxa Initiative organised its biggest General Assembly meeting yet. Over 40 participants joined us at the lively city centre of Dublin, Ireland. The overarching theme of the meeting was collaboration. Read more: beneluxa.org/General_Assemb…

A joint analysis shows that collaboration on HTA between the Beneluxa Initiative member countries would likely not result in added benefit conclusions that would be different from added benefit conclusions in national procedures. Further information: beneluxa.org/publication_fe…

Joint HTA for Hemgenix - Belgium and the Netherlands aim to undertake a joint assessment of Hemgenix (a gene therapy to treat adults with severe and moderately severe haemophilia B) as part of a reimbursement application by the manufacturer. Read more: beneluxa.org/news1

The health ministers from the countries participating in the Beneluxa-initiative met during the EPSCO meeting on November 30th to exchange on their collaboration. More information: beneluxa.org/ministers_EPSC…

The steering committee of the #Beneluxa Initiative welcomes new chair the Netherlands and vice-chair Ireland. Read more: beneluxa.org/beneluxa_newch…

The #Beneluxa Initiative announces successful conclusion of #Libmeldy price negotiations, directly benefiting patients in three countries. Read more here: beneluxa.org/libmeldy_concl…

The Beneluxa Initiative held a #Beneluxa scoping webinar on #Alzheimer's disease. 30 experts, representing prescribers, public payers and patient organizations joined to discuss the evolving landscape of #Alzheimer's treatment. 👉beneluxa.org/scoping_webina…

On June 25, 2024, the Steering Committee of the Beneluxa Initiative met in Brussels, Belgium to discuss ongoing and potential future activities 🌟 Find more information on the meeting here: beneluxa.org/steering_commi…

Belgium and the Netherlands, members of the #Beneluxa Initiative, completed a joint #HTA report on the gene therapy #Hemgenix®. The full report can be consulted on the public website of Zorginstituut Nederland: zorginstituutnederland.nl/publicaties/ad…

After a joint assessment of gene therapy Hemgenix®, Belgium & the Netherlands opted for individual negotiations, mainly due to different finance mechanisms of SoC products. Full statement here: beneluxa.org/Hemgenix_indiv…

🏛️ Exciting updates from the Beneluxa Initiative! On Dec 9-10, 2024, the General Assembly & Steering Committee Meeting took place in Luxembourg to discuss collaboration, future activities and strategic planning. Find more information on the website.